BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 24589536)

  • 1. Ruxolitinib for the treatment of primary myelofibrosis.
    Swaim SJ
    Am J Health Syst Pharm; 2014 Mar; 71(6):453-62. PubMed ID: 24589536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical management of patients with myelofibrosis receiving ruxolitinib.
    Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
    Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
    Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
    Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib: a new treatment option for myelofibrosis.
    Ganetsky A
    Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
    Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
    Deisseroth A; Kaminskas E; Grillo J; Chen W; Saber H; Lu HL; Rothmann MD; Brar S; Wang J; Garnett C; Bullock J; Burke LB; Rahman A; Sridhara R; Farrell A; Pazdur R
    Clin Cancer Res; 2012 Jun; 18(12):3212-7. PubMed ID: 22544377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
    Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
    Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
    Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
    Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib: a review of its use in patients with myelofibrosis.
    Plosker GL
    Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for the treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
    Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
    Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.